Anas Younes: Decade-Long Persistence of CD19 CAR T Cells in B Cell Lymphomas
oncodaily - Anas Younes, Chief Medical Officer and Head of Haematology R&D at AstraZeneca, shared on LinkedIn: “While these findings demonstrate that CART19 cells can persist for more than 10 years in […]
AI Summary: Long-term follow-up shows CD19-directed CAR‑T cells can persist for a decade in patients with B‑cell lymphomas, associating with sustained remissions and reshaping expectations about durability, retreatment and long-term toxicity. These findings prompt rethinking of follow-up care and suggest cellular therapies may offer far longer benefits than anyone dared hope.
Wungki Park: First Map of Acquired Resistance to Daraxonrasib in Pancreatic Cancer
oncodaily - Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “The first map of acquired resistance to the tri-complex RAS(ON) inhibitor daraxonrasib in PDAC published today in […]
AI Summary: Researchers have charted acquired resistance mechanisms to the RAS(ON) inhibitor daraxonrasib in pancreatic cancer, identifying pathways that suggest rational combination therapies. The resistance map offers a practical roadmap to improve durability of responses, nudging drug developers to pair daraxonrasib with agents that block the escape routes tumors exploit.
Study ties estrogen-based menopausal hormone therapy to lower Alzheimer's risk
medicalxpress - Women on regimens of estrogen-only menopausal hormone therapy are at reduced risk of Alzheimer's disease, a study by Stanford Medicine investigators has found. Because estrogen-only therapy is generally prescribed for women without a uterus, most of these…
AI Summary: Observational research linked estrogen‑based menopausal hormone therapy to fewer Alzheimer’s‑related brain changes on imaging, suggesting a potential protective association. Investigators stress that timing, confounding factors and observational design limit causal claims, so randomized trials and careful risk‑benefit assessment remain necessary before changing clinical practice — or anyone swapping kale for HRT on a whim.
A surprising triple treatment completely clears hiv in newborn primates
sciencedaily - Researchers have found a striking new way to potentially eliminate HIV soon after infection using a one-time combination of three therapies. In newborn nonhuman primates treated within three days of exposure, the regimen—standard antiretroviral drugs, bro…
AI Summary: A preclinical study reports that a triple‑dose therapeutic regimen eradicated detectable HIV in newborn primates, offering proof‑of‑concept that very early, intensive intervention might prevent persistent infection. Translation to human infants will require careful clinical trials, ethical oversight and long follow‑up, but the findings mark a hopeful, if cautious, step toward functional cures.
FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma
oncodaily - The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adults with multiple myeloma who have […]
AI Summary: Bristol Myers Squibb secured FDA approval of a first‑in‑class protein‑degrader regimen for multiple myeloma, cleared as a combination with daratumumab, hyaluronidase and dexamethasone. The nod marks a notable shift toward targeted degrader strategies in hematologic oncology and gives clinicians another option for patients with advanced disease.